HYUNDAI FEED Inc - Asset Resilience Ratio

Latest as of June 2025: 11.71%

HYUNDAI FEED Inc (016790) has an Asset Resilience Ratio of 11.71% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 016790 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩12.36 Billion
≈ $8.37 Million USD Cash + Short-term Investments

Total Assets

₩105.49 Billion
≈ $71.49 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2015–2024)

This chart shows how HYUNDAI FEED Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of HYUNDAI FEED Inc.

Liquid Assets Composition Over Time

This chart breaks down HYUNDAI FEED Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of HYUNDAI FEED Inc to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩12.36 Billion 11.71%
Total Liquid Assets ₩12.36 Billion 11.71%

Asset Resilience Insights

  • Moderate Liquidity: HYUNDAI FEED Inc has 11.71% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

HYUNDAI FEED Inc Industry Peers by Asset Resilience Ratio

Compare HYUNDAI FEED Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
B&G Foods Inc
NYSE:BGS
Packaged Foods 1.99%
Saputo Inc
TO:SAP
Packaged Foods 3.36%
Lotus Bakeries
BR:LOTB
Packaged Foods 2.28%
COFCO Tunhe Sugar Co Ltd
SHG:600737
Packaged Foods 0.08%
Nongshim
KO:004370
Packaged Foods 25.51%
Grupo Bimbo S.A.B. de C.V
MX:BIMBOA
Packaged Foods 0.15%
Avanti Feeds Limited
NSE:AVANTIFEED
Packaged Foods 65.24%
Juewei Food Co Ltd
SHG:603517
Packaged Foods 3.18%

Annual Asset Resilience Ratio for HYUNDAI FEED Inc (2015–2024)

The table below shows the annual Asset Resilience Ratio data for HYUNDAI FEED Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 9.40% ₩11.00 Billion
≈ $7.45 Million
₩116.98 Billion
≈ $79.28 Million
+8.94pp
2023-12-31 0.46% ₩500.00 Million
≈ $338.84K
₩108.36 Billion
≈ $73.43 Million
-2.08pp
2022-12-31 2.55% ₩6.91 Billion
≈ $4.68 Million
₩271.27 Billion
≈ $183.84 Million
-3.21pp
2021-12-31 5.75% ₩5.39 Billion
≈ $3.66 Million
₩93.77 Billion
≈ $63.55 Million
-8.57pp
2020-12-31 14.33% ₩14.07 Billion
≈ $9.53 Million
₩98.21 Billion
≈ $66.55 Million
+12.11pp
2019-12-31 2.21% ₩2.15 Billion
≈ $1.46 Million
₩97.38 Billion
≈ $65.99 Million
-6.09pp
2018-12-31 8.30% ₩7.81 Billion
≈ $5.29 Million
₩94.05 Billion
≈ $63.74 Million
-10.90pp
2017-12-31 19.20% ₩16.29 Billion
≈ $11.04 Million
₩84.84 Billion
≈ $57.49 Million
+5.98pp
2016-12-31 13.22% ₩10.95 Billion
≈ $7.42 Million
₩82.82 Billion
≈ $56.13 Million
+2.82pp
2015-12-31 10.40% ₩11.17 Billion
≈ $7.57 Million
₩107.39 Billion
≈ $72.78 Million
--
pp = percentage points

About HYUNDAI FEED Inc

KQ:016790 Korea Packaged Foods
Market Cap
$126.96 Million
₩187.34 Billion KRW
Market Cap Rank
#18387 Global
#819 in Korea
Share Price
₩994.00
Change (1 day)
+0.00%
52-Week Range
₩994.00 - ₩994.00
All Time High
₩15077.70
About

HYUNDAI FEED Inc. engages in the manufacture and sale of formulated feed. Its primary products include poultry and pig feed. The company also engages in the biopharmaceutical business. In addition, it focuses on the development and commercialization of immunotherapies for cancer. Further, the company's lead product includes oregovomab, an immunotherapy for ovarian cancer. Additionally, it is invo… Read more